Surgical Heller Myotomy Research Articles

576. ESOPHAGEAL ACHALASIA: VERY LONG FOLLOW-UP STUDY ON PATTERNS AND COMPLICATIONS OF POST MYOTOMY GERD

Abstract Since the adoption of the Heller myotomy, surgeons have modified the original technique to balance the cure of dysphagia and the consequent cardial incontinence. Surprisingly, today post POEM 30-50% erosive-ulcerative esophagitis rates are by some put inside normality. Our group had the opportunity to follow up methodically patients submitted to Heller myotomy since 1955. Aim is to provide information on long-term outcomes of Heller myotomy for esophageal achalasia with or without an antireflux fundoplication. In first instance 83 patients underwent a long abdominal myotomy (AM 1955-72), 30 patients a transthoracic myotomy according to Ellis (TM 1973-78), 364 patients the Heller-Dor operation with intraoperative manometry to calibrate myotomy, length and pressure of the Dor fundoplication (HD 1979-2021). Starting on 1973 these patients underwent a prospective follow-up program of timed lifelong clinical, radiological, endoscopic evaluations. Since 1973 an endoscopic-radiologic-clinical timed follow up has been established. GERD symptoms/esophagitis were evaluated. AM, TM and HD groups were followed up for a median period of 25, 27, 14 years respectively. GERD symptoms-esophagitis occurred in AM 29.5%-28.1%, TM 30%-30%, HD 6.6%-5.8%. Timing of esophagitis after HD revealed: early onset (6-24 months) in 8 (2.2%), late onset (25 months-14 years) in 13 (3.6%). PPIs controlled reflux symptoms (71%vs14%, p<0.0001) but not esophagitis (43%vs46%, p= 0.075). Among 50 patients with erosive/ulcerative reflux esophagitis, Barrett’s esophagus was diagnosed in 21 (42%) at a median period of 112 months since myotomy. In this group low-grade dysplasia occurred in 12 (24%) and high grade dysplasia/adenocarcinoma in 5 (10%). After surgical Heller myotomy not associated with an efficient antireflux procedure, GERD occurred in 30% which decreased to 6% after HD. A Heller-Dor operation is a competitive option for the cure of esophageal achalasia if this operation is performed according to the rules of surgical physiology learned by means of intraoperative manometry. The adoption of POEM in alternative to HD for the treatment of achalasia should be questioned.

ID: 3522391 THE RISK OF NEEDING AN ANTIREFLUX PROCEDURE AFTER PER ORAL ENDOSCOPIC MYOTOMY AND SALVAGE WITH TRANSORAL INCISIONLESS FUNDOPLICATION

Gastroesophageal reflux (GERD) is the main potential limitation of per-oral endoscopic myotomy (POEM) whereas a surgical Heller myotomy has the benefit of an anti-reflux wrap. Transoral incisionless fundoplication (TIF) is an endoscopic anti-reflux procedure that can be used as rescue therapy for post POEM GERD. However, prognostic indicators to predict which patients are most at risk for post POEM GERD are lacking. This study aims to evaluate management of post POEM GERD and the risk for needing an anti-reflux procedure.

ID: 3524257 TANDEM PER ORAL ENDOSCOPIC MYOTOMY AND TRANSORAL INCISIONLESS FUNDOPLICATION: A STRATEGY TO REDUCE REFLUX AFTER PER ORAL ENDOSCOPIC MYOTOMY

Per oral endoscopic myotomy (POEM) is an effective treatment for achalasia with outcomes comparable to surgical Heller myotomy. However, POEM has been shown to have higher post-procedural rates of abnormal acid exposure and esophagitis compared to Heller myotomy.

Advances and caveats in modern achalasia management.

Achalasia is a rare esophageal motility disorder characterized by the incomplete relaxation of the lower esophageal sphincter (LES) and impaired peristaltic activity. The advent of high-resolution manometry (HRM) and the rapidly evolving role of therapeutic endoscopy have revolutionized the approach to the diagnosis and management of achalasia patients in the last decade. With advances in HRM technology and methodology, fluoroscopy and EndoFlip, achalasia can be differentiated into therapeutically meaningful phenotypes with a high degree of accuracy. Further, the newest treatment option, per-oral endoscopic myotomy (POEM), has become a staple therapy following the last 10 years of experience, and recent randomized trials appear to show no difference between POEM, graded pneumatic dilatation and surgical Heller myotomy in terms of short- and long-term efficacy or complication rate. On the other hand, how treatment outcomes are measured as well as the risk of reflux following therapy remain areas of contention. This review aims to summarize the recent advancements in achalasia testing and therapy, describes the recent randomized clinical trials as well as their potential setbacks, and touches on the future of personalizing achalasia treatment.

Advances in POEM for Achalasia: Optimal Technique, Post-POEM GERD

Peroral endoscopic myotomy (POEM) is a novel procedure introduced into clinical practice by Inoue in 2010 for the treatment of achalasia. It is a safe and efficient procedure but with unknown long-term consequences of post-treatment gastroesophageal reflux (GER). Compared with surgical Heller myotomy with fundoplication, endoscopic myotomy has no standardized complementary procedure to prevent reflux. Several techniques aiming at diminishing the risk of post-procedural reflux have been described in the literature with promising outcomes. The double-scope technique (DST) is recommended by the Japanese Consensus for POEM, but endoscopic fundoplication procedures such as transoral incisionless fundoplication (TIF) and fundoplication using the NOTES approach (POEM-F) may play a major role in the primary prophylaxis for post-POEM GER. Reflux occurring after endoscopic myotomy is a clinically relevant issue. Different techniques to minimize or prevent post-procedural reflux are now available but further research is needed.

Distal esophageal spasm: Update on diagnosis and management in the era of high-resolution manometry.

Distal esophageal spasm (DES) is a rare major motility disorder in the Chicago classification of esophageal motility disorders (CC). DES is diagnosed by finding of ≥ 20% premature contractions, with normal lower esophageal sphincter (LES) relaxation on high-resolution manometry (HRM) in the latest version of CCv3.0. This feature differentiates it from achalasia type 3, which has an elevated LES relaxation pressure. Like other spastic esophageal disorders, DES has been linked to conditions such as gastroesophageal reflux disease, psychiatric conditions, and narcotic use. In addition to HRM, ancillary tests such as endoscopy and barium esophagram can provide supplemental information to differentiate DES from other conditions. Functional lumen imaging probe (FLIP), a new cutting-edge diagnostic tool, is able to recognize abnormal LES dysfunction that can be missed by HRM and can further guide LES targeted treatment when esophagogastric junction outflow obstruction is diagnosed on FLIP. Medical treatment in DES mostly targets symptomatic relief and often fails. Botulinum toxin injection during endoscopy may provide a temporary therapy that wears off over time. Myotomy through peroral endoscopic myotomy or via surgical Heller myotomy can provide long term relief in cases with persistent symptoms.

Therapeutic options in oesophageal dysphagia.

High-resolution manometry enables the categorization of patients with oesophageal dysphagia caused by oesophageal motility disorders into diagnostic categories according to the Chicago Classification. This Review provides an overview of the literature concerning treatment options for patients with dysphagia associated with achalasia, hypercontractile disorders and hypocontractility disorders of the oesophagus. In achalasia, pharmacotherapy and botulinum toxin are less effective than pneumatic dilation or surgical Heller myotomy, which had comparable efficacy in the largest controlled trial to date. Peroral endoscopic myotomy is a novel therapeutic modality that is currently being evaluated in controlled trials versus pneumatic dilation or surgical myotomy. A variety of medical treatments have been evaluated in hypermotility disorders, but only botulinum toxin injection yielded favourable results in a single controlled trial. Few studies have addressed the treatment of dysphagia in patients with oesophageal hypomotility. A variety of prokinetic agents have been studied, but there is no evidence of clinically relevant efficacy from controlled trials.

Peroral Endoscopic Myotomy Is a Viable Option for Failed Surgical Esophagocardiomyotomy Instead of Redo Surgical Heller Myotomy: A Single Center Prospective Study

Surgical Heller myotomy has high rates of successful long-term results, but failed cases still remain. Moreover, the treatment strategy in patients with surgical myotomy failure is controversial. Recently, peroral endscopic myotomy (POEM) was reported to be efficient and safe in primary treatment of achalasia. In this study, we aimed to evaluate the efficacy and safety of POEM for surgical myotomy failure as a rescue second-line treatment, and we discuss the treatment options adapted in achalasia recurrence. A total of 315 consecutive achalasia patients received POEM from September 2008 to December 2012 in our hospital. Eleven (3.5%) patients who had persistent or recurrent achalasia and had received surgical myotomy as a first-line treatment from other hospitals were included in this study. Patient background, barium swallow studies, esophagogastroduodenoscopy (EGD), manometry, and symptom scores were prospectively evaluated. In principle, all patients in whom surgical myotomy failed received pneumatic balloon dilatation (PBD) as the first line "rescue" treatment, and only if PBD failed were patients considered for rescue POEM. The PBD alone was effective in 1 patient, and in the remaining 10 patients, rescue POEM was performed successfully without complications. Three months after rescue POEM, significant reduction in lower esophageal sphincter (LES) resting pressures (22.1 ± 6.6 mmHg vs 10.9 ± 4.5 mmHg, p < 0.01) and Eckardt symptom scores (6.5 ± 1.3 vs 1.1 ± 1.3, p < 0.001) were observed. Short-term results of POEM for failed surgical myotomy were excellent. Long-term results are awaited.

Per-oral endoscopic myotomy for achalasia: An American perspective

Achalasia is an uncommon esophageal motility disorder characterized by the selective loss of enteric neurons leading to absence of peristalsis and impaired relaxation of the lower esophageal sphincter. Per-oral endoscopic myotomy (POEM) is a novel modality for the treatment of achalasia performed by gastroenterologists and surgeons. It represents a natural orifice transluminal endoscopic surgery (NOTES) approach to Heller myotomy. POEM has the minimal invasiveness of an endoscopic procedure that can duplicate results of the surgical Heller myotomy. POEM is conceptually similar to a surgical myotomy without the inherent external incisions and post-operative care associated with surgery. Initial high success and low complications rates promise a great future for this technique. In fact, POEM has been successfully performed on patients with end-stage achalasia as an initial treatment reserving esophagectomy for those without good response. The volume of POEMs performed worldwide has grown exponentially. In fact, surgeons who have performed Heller myotomy have embraced POEM as the preferred intervention for achalasia. However, the niche of POEM remains to be defined and long term results are awaited. We describe our experience with POEM having performed the first POEM outside of Japan in 2009, the evolution of our technique, and give our perspective on its future.

Modern management of achalasia

The goals in the treatment of achalasia are threefold: 1) relieving the symptoms, particularly dysphagia and bland regurgitation; 2) improving esophageal emptying by disrupting the poorly relaxing lower esophageal sphincter (LES); and 3) preventing the development of megaesophagus. Although achalasia cannot be permanently cured, excellent palliation is available in over 90% of patients, especially those with pneumatic dilation and laparoscopic Heller myotomy. The efficacy for short- and long-term therapy seems to be similar when performed by experts. Pneumatic dilation done as an outpatient surgery disrupts the LES muscle from within by using balloons of progressively larger diameter (3.0, 3.5, and 4.0 cm). Repeat dilations may be required; secondary severe gastroesophageal reflux disease (GERD) is rare, but approximately 2% of patients will have an esophageal perforation. A surgical Heller myotomy is now being done laparoscopically through the abdomen that cuts the LES and extends the myotomy 2 to 3 cm onto the stomach. Usually 2 days of hospitalization is required, and patients can normally return to work in 1 to 2 weeks. Severe GERD with esophagitis and peptic stricture is a common complication; therefore, most surgeons combine the myotomy with an incomplete fundoplication. Medical therapy is much less effective than these invasive procedures. Smooth muscle relaxants (nitrates and calcium channel blockers) taken immediately before meals improve dysphagia, but side effects and drug tolerance are common. The injection of botulinum toxin (100 to 200 units) endoscopically into the LES gives short-term relief of symptoms and improves esophageal emptying. This treatment is most effective in the elderly, as symptom relief can last up to 1 to 2 years with a single injection. Several studies suggest the most cost-effective management of achalasia is initial treatment with pneumatic dilation.

Evaluation of scar formation after botulinum toxin injection or forced balloon dilation to the lower esophageal sphincter.

It has been postulated that nonsurgical treatments for achalasia cause fibrosis, increasing the risk of surgical Heller myotomy. The goal of this study was to evaluate fibrosis, muscle fracture, and esophageal inflammation after these treatments. Eighteen female swine were divided into three groups: 6 were euthanized and their lower esophageal sphincters were harvested (group 1); 6 underwent botulinum toxin injection (group 2); and 6 underwent forced balloon dilatation (group 3). Groups 2 and 3 were euthanized 30 days later and LESs harvested. LESs, were evaluated with trichrome and hematoxylin and eosin (H&E) preparations. Results for both trichrome and H&E slides were the same: severe inflammation in groups 2 and 3 but only minimal inflammation in group 1 (p <0.05) and mild fibrosis in groups 2 and 3 and none in group 1 (p <0.05). Botulinum toxin injection and forced balloon dilatation caused significant inflammation in the esophagus of the swine, which would be consistent with the injury caused by reflux. Forced balloon dilatation and botulinum toxin caused fibrosis and may increase surgical risk.

Balloon Dilation—Assisted Laparoscopic Heller Myotomy and Dor Fundoplication

Two methods are currently used in the treatment of achalasia: endoscopic balloon dilation and surgical Heller myotomy. Laparoscopy has come into use in achalasia surgery, and good outcomes have been achieved. This study included 11 patients (mean age, 30.7 years). Balloon dilation-assisted laparoscopic Heller myotomy and Dor fundoplication were performed in all patients. A 36-F orogastric tube was placed under visualization. The balloon of the tube was placed in the esophagogastric junction. After laparoscopic cardiomyotomy, the balloon was removed and Dor fundoplication was performed. The mean operative time was 90 minutes. The patients were discharged on the second and third postoperative days (mean [standard deviation], 3 +/- 0.46). One month after the operation, the patients were tested with barium swallowing, and no complications or recurrences were observed. Laparoscopic distal esophagomyotomy combined with partial fundoplication may be the surgical approach of choice in achalasia because it is safer, provides good to excellent relief of symptoms and excellent cosmetic results, involves a shorter hospital stay, and is easy to execute. Balloon dilation makes myotomy easier because it separates the muscle fibers. Placing and insufflation of the balloon become safer because the entire procedure is executed under visualization; thus, excessive dilation is avoided.